BDR Pharma acquires Acme’s oral solid formulations business. The deal expands BDR Pharma’s portfolio in pharmaceutical manufacturing. Acme specializes in producing tablets and capsules for global markets.
BDR Pharma acquires Acme Formulation’s oral solid formulations business from shareholders, including private equity firm PAG. The deal expands BDR’s contract development and manufacturing (CDMO) platform, adding expertise in thyroid medications, women’s healthcare products, and general medicines.
BDR Pharmaceuticals is acquiring $100 million in U.S. manufacturing assets to strengthen its production capabilities. The deal remains under advanced negotiations, with a final decision anticipated in the coming months. This expansion aims to enhance the company’s global operational footprint and capacity.
A private equity-led consortium acquires a 9.3% stake in **BDR Pharmaceuticals International** for **₹685 crore** (~$88 million). The deal involves **Multiples Alternate Asset Management Pvt. Ltd** leading the investment in the Mumbai-based pharmaceutical company.
